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Objective: Myocardial infarction (MI) is often preceded by severe chest pain. The use of
inflammatory markers to distinguish between chest pain of cardiac and non cardiac origin
are not well reported. The aim of the study was to distinguish the chest pain of non cardiac
and cardiac origin by using reliable inflammatory markers.
Methods: The present study enrolled 80 subjects including chest pain which lead to
myocardial infarction (n¼40), non-cardiac chest pain (CP) patients (n¼20) and healthy
volunteers (N) (n¼20). Leukotriene B4 (LTB4) and thromboxane B2 (TXB2) levels were
analyzed along with hs-CRP.
Results: Receiver operating characteristic (ROC) curve analysis showed LTB4 and TXB2 to be
a good discriminator between patients with chest pain of cardiac and non cardiac in origin.
The area under the curve was found to be 0.988 and 0.925 for LTB4 and TXB2, respectively
when compared with hs-CRP. The sensitivity and specificity of LTB4 and TXB2 were found
to be 90, 85% and 95, 90%, respectively.
Conclusion: The measurement of LTB4 and TXB2 levels may therefore be useful to distin-
guish the chest pain leading to MI from that of non cardiac in origin and for the man-
agement of the disease.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction myocardial infarction, and need for revascularization pro-Myocardial infarction (MI) is one of the major causes of mor-
tality and morbidity in the world.1 Inflammation plays a
central role in the formation as well as rupturing of plaque
leading to MI. The actual mechanism of plaque rupturing is
still not known. High sensitivity C-reactive protein (hs-CRP),
a biomarker for inflammation is viewed as a prominent
partaker in endothelial dysfunction and atherosclerosis.2,3
Blake and Ridker have shown that elevated hs-CRP can pre-
dict risk of cardiovascular events (including death, acute2308078.
l.com (M. Indira).
2013, Cardiological Societcedures) in patients with acute coronary syndromes (ACS).4
Studies of genetic polymorphisms have established
significant associations for the leukotriene pathway with
early signs of atherosclerosis5,6 as well as the development
of stroke and myocardial infarction.7,8 Reports show that
genetic variation in the gene ALOX5AP (arachidonic 5-lip-
oxygenase-activating protein) and LTA4H (leukotriene A4
hydrolase) contribute to the risk of myocardial infraction
and stroke in Icelandic, Scottish and European-American
population.9y of India. All rights reserved.
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(COX) and lipoxygenase (LOX) in the heart and coronary blood
vessels, to numerous compounds with a variety of actions
including vasodilation, vasoconstriction, enhanced myocar-
dial injury and cardioprotection. Five-lipoxygenase (5-LOX),
the rate-limiting enzyme in the biosynthesis of leukotrienes
from AA, has been associated with the development of
atherosclerosis in mouse models, and a 5-LOX promoter
repeat polymorphism has been implicated in atherosclerosis
in humans.10 5-LOX uses 5-lipoxygenase-activating protein
(FLAP) to convert AA into leukotriene A4 (LTA4), an unstable
epoxide. In cells equipped with LTA4H, such as neutrophils
and monocytes, LTA4 is converted to leukotriene B4 (LTB4),
which is a powerful chemoattractant for neutrophils acting at
(leukotriene B4 receptor) BLT1 and BLT2 receptors on the
plasma membrane of these cells.11
COX-1 and its AAmetabolites have been long recognized to
possess important roles in the myocardium during acute ep-
isodes of myocardial ischemia and reperfusion.12 COX con-
verts AA to prostaglandins and thromboxane A2 (TXA2). TXA2
is very unstable and is hydrolyzed to stable thromboxane B2
(TXB2). Takase et al observed that the production of LTB4 and
TXB2 in systemic artery blood was elevated during acute stage
of AMI.13 Sowe hypothesized that levels of LTB4 and TXB2may
point out the biochemical differences between non cardiac
chest pain and chest pain of cardiac origin leading to MI. We
have selected young subjects with cholesterol level less than
250 mg/dl. Cholesterol has been considered as a risk factor for
MI. We also wanted to study the correlation between choles-
terol levels, inflammatory markers and occurrence of MI
especially in young subjects. Hence the present study focused
on the levels of LTB4 and TXB2 in young subjects (age below
45 yrs) whose cholesterol levels were below 250 mg/dl.2. Methods
2.1. Patient selection
Eighty subjects in the age group 35e45 years were enrolled in
the study. They were categorized into three groups: the
myocardial infarction (MI) group (n ¼ 40) at presentation, non
cardiac chest pain (CP) (n ¼ 20) patients and healthy volun-
teers (N) group (n¼ 20). Patients admitted in the intensive care
unit (ICU) of cardiology unit in PRS hospital, Trivandrum, India
with clinical diagnosis of MI were included in the study. The
inclusion criteria were patients with prolonged chest pain
more than 30min, ST segment elevationmore than 0.1 mV on
at least two adjacent ECG leads or positive biomarkers. These
patients were the oneswith first episode of chest pain and had
neither past history of such clinical symptoms nor were on
any knownmedications for the same. Cholesterol levels below
250 mg/dl and age below 45 years were also considered in the
inclusion criteria. The exclusion criteria include those with
chest pain less than 30 min or more than 12 h, no ST segment
elevation, T inversion or ST depression in ECG, those with
known renal or hepatic dysfunction, bleeding disorder or any
malignancy. Patients or bystanders who were unable to give
consent for the study were also excluded from the present
study. The controls were healthy individuals with systolicblood pressure/diastolic blood pressure (SBP/DBP) ¼ 135/
85 mmHg or less, with no risk factors of CAD or clinical
symptoms of any other organic disease. The CP patients were
individuals with normal blood pressure and ECG, the chest
pain was non cardiac in origin, Cholesterol levels was below
250 mg/dl and age below 45 years. As per the selection criteria
in each group, subjects were recruited with their informed
consent and a detailed data collection was done. The institu-
tional ethics committee approved the study protocol.
2.2. Blood sample collection
The peripheral whole blood was collected in plain and sodium
citrate (3.2%) vacutainer tubes. Subsequently, serum and
plasma were separated by centrifugation at 1000 g for 10 min.
For healthy individuals blood samples were collected
randomly. From MI and CP patients, blood samples were
collected at the time of admission to the ICCU before admin-
istration of any treatment.
2.3. Study protocol
Serum level of total cholesterol was measured by standard
enzymatic method using kit (Agappe Diagnostics, India) and
expressed as milligram per deciliter of serum. The level of
hs-CRP in serum was estimated by using CRP-ultrasensitive
latex turbidimetry kit according to the manufacturer’s in-
struction (Spinreact, Spain) and expressed as milligram per
deciliter.
Activities of 5-LOX and COX were evaluated in the mono-
cytes. Monocytes were separated from whole blood by the
method of Hutch (1996).14 The activity of 5-LOX was deter-
mined in monocytes by the method of Axelrod et al (1981)15
and activity of COX by the method of Shimazu et al (1981).16
LTB4 concentrationwere determined in the serum by using
enzyme immunoassay kit as described by the manufacturer
(R&D systems, USA). Similarly, TXB2 was measured as
described by the manufacturer of an enzyme immunoassay
kit (Cayman Chemicals, USA). The amount of LTB4 and TXB2
were expressed as picogram/milliliter of serum.
2.4. Statistical analysis
The data’s were represented as mean  standard deviation
(SD). One way ANOVA was applied to determine the signifi-
cance of biochemical parameters among the groups.
Duncan’s post-hoc multiple comparison tests of significant
differences among groups were determined. Receiver oper-
ating characteristic (ROC) curve were established to evaluate
the diagnostic value of LTB4 and TXB2 for differentiating
between chest pain of cardiac and non cardiac in origin. A
p< 0.05 was considered significant. All statistical analysis was
performed using statistical software SPSS (version 17,
Chicago, IL).3. Results
The clinical characteristics of the CP and MI groups are pre-
sented in Table 1. There were no statistical differences
Table 1 e Clinical characteristics of the MI, CP and N patients.
Characteristics MI patients (n ¼ 40) CP patients (n ¼ 20) N (n ¼ 20)
Age (years) 41.87  5.82 40.85  5.81 40.01  5.78
Male/female 37/3 19/1 19/1
RBS 114.95  15.42 110.2  16.28 102.3  13.75
TC (mg/dl) 222.95  32.45 214.3  29.87 211.5  28.16
HDL (mg/dl) 47.8  9.15 48  10.02 55  12.3
LDL (mg/ml) 98  15.12 85  13.24 82  13.17
Total count (cells/cumm) 9330  1811.80 7705  1319.28 7915  1108.54
Platelet Count (lakhs/cumm) 3.19  0.65 2.67  0.28 2.45  0.25
N (%) 67.50  9.57 63.15  8.9 62.75  8.5
E (%) 5.4  1.63 4.6  1.16 4.3  1.03
L (%) 28.88  6.65 25.60  5.61 24.13  5.20
Hb (gm/dL) 16.13  2.79 14.71  2.62 15.8  2.68
ESR (mm/hr) 8.15  2.38a 3.47  0.65 3.2  0.43
Urea (mg/dl) 26.62  6.35 24.50  5.82 24.35  5.21
Creatinine (mg/dl) 1.14  0.32 0.97  0.12 0.84  0.10
Na (mEq/L) 140.1  6.12 135.65  4.22 124  3.86
K (mEq/L) 4.09  0.55 3.49  0.46 3.19  0.41
SGPT (IU/L) 58.6  13.25a 47.85  10.52 44.25  8.51
Fibrinogen (mg/dl) 480  35.28a 196  22.84 175  20.13
RBS: random blood sugar, TC: total cholesterol, HDL: high-density lipoprotein, LDL: low-density lipoprotein, N: neutrophil, E eosinophil, L:
leukocytes, Hb: hemoglobin, ESR: erythrocyte sedimentation rate, Na: Sodium, K: potassium, SGPT: serum glutamate pyruvate transaminase.
Values are expressed as mean  SD.
a p < 0.05.
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considered variables except for ESR which was slightly
enhanced in MI patients, but was in the normal range. In
addition, other biomarkers, such as SGPT and fibrinogen levels
increased inMI patients when compared to that in CP subjects
(Table 1). The level of total cholesterol in serum of MI patients
showed no significant increase when compared to CP and N
subjects (Table 1). The total cholesterol levels were within the
normal range in all the subjects.
The level of hs-CRP detected in serum of MI patients
showed a significant increase when compared to other
groups (Table 2). The marker enzymes of the arachidonic
acid pathway such as 5-LOX and COX were studied in the
three groups. The activities of both 5-LOX and COX wereTable 2 e Evaluation of hs-CRP, 5-LOX, COX,LTB4, TXB2 in









hs-CRP (mg/L) 0.82  0.14a 1.6  0.28a 5.4  0.55b
5-LOX ( 104 OD
shift at 234 nm
/min/mg protein)
2. 97  0.62a 3.5  0.84a 6.47  1.8b




3.44  0.54a 3.8  0.64a 5.77  0.82b
LTB4 (pg/ml) 242.24  20.4a 295  22.5a 2024.28  77.5b
TXB2 (pg/ml) UD UD 70.82  8.2b
UD e undetectable level (<10 pg/ml) in the serum with the specific
EIA kit. Values are mean  SD. p < 0.05. Different superscript (a, b)
indicates the values are significantly different.significantly elevated in MI subjects when compared to CP
and N ( p < 0.001). Similarly the level of TXB4 increased in the
serum along with a nine fold increase in LTB4 level in MI
patients when compared to CP and N subjects ( p < 0.001)
(Table 2).
ROC curve analysis was done to demonstrate the useful-
ness of LTB4 and TXB2 as an individual risk determinant in
subjects with chest pain of cardiac and non cardiac in origin.
The area under curve (AUC) of LTB4 and TXB2 was 0.988 and
0.925, respectively when compared to hs-CRP (0.916) (Table 3)
(Fig. 1). The sensitivity and specificity of hs-CRP, TXB2 and
LTB4 were 75, 85, 90% and 80, 90, 95%, respectively.4. Discussion and conclusions
Chest pain is an important symptom shown by most of the
patients prior to a severe MI. But there also prevail chest pains
of non cardiac in origin. The plaque which ruptures leading to
MI is filled with cholesterol deposits, but studies have shown
that only 35% of the patients with cholesterol levels greater





PPV NPV Accuracy AUC
hs-CRP 75 80 88 62 77 0.916
TXB2 85 90 94 75 87 0.925
LTB4 90 95 97 82 92 0.988
PPV: positive predictive value, NPV: negative predictive value, AUC:






Fig. 1 e Receiver operating characteristic (ROC) curve of
different markers.
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included.
hs-CRP is considered as a biomarker of inflammation
especially inMI patients. The level of hs-CRP in theMI subjects
increased significantly when compared to CP and N (p < 0.05).
Our observation that hs-CRP levels were enhanced in MI
patients is in support of the report by Ridker et al18 which
states that hs-CRP predicts not only incident myocardial
infarction and cardiovascular death, but also the risk of
ischemic. hs-CRP showed an AUC of 0.916 with 75% sensi-
tivity, 80% specificity and 77% accuracy.
Our study was mainly focused on LTB4 and TXB2. Their
production depends on the activities of the key enzymes 5-
LOX and COX. Their activities were enhanced in the MI pa-
tients indicating the upregulation of AA pathway and pro-
duction of LTB4 and TXB2. This is supported by the enhanced
levels of LTB4 and TXB2 in MI subjects. Spanbroek et al,
19 re-
ported that 5-LOX is the main LOX expressed within athero-
sclerotic lesions. Polymorphisms in the 5-LOX gene promoter
and certain 5-LOX-activating protein haplotypes have been
linked to an increased risk of infarction and stroke.20 van der
Net et al21 reported that genetic variation in the ALOX5AP gene
contributes to CHD risk in patients with familial hypercho-
lesterolemia. A study by Wong et al22 has reported the
expression of COX in ischemic human myocardium and in
dilated cardiomyopathy, but not in normal cardiomyocytes
indicating a role of COX in cardiac disease.
The present study revealed a significant increase in the
LTB4 levels in MI subjects. Takase et al,
13 have observed that
LTB4 levels are elevated in acute myocardial patients during
acute stage. Sanchez Galan et al,11 characterized the expres-
sion of 5-LOX pathway and LTB4 receptors in blood and pla-
ques from patients with carotid atherosclerosis. TXB4 levelwas increased in the serum of MI patients. Studies by
Moscardo et al,23 have showed that residual-COX-1 activity
and epinephrine enhance TXA2-dependent platelet function,
which may reduce the clinical benefit of aspirin in patients
with AMI. LTB4 showed an AUC of 0.988 with 90% sensitivity,
95% specificity and 92% accuracy, indicating its usefulness for
the management of disease.
In conclusion, the increase in oxidative stress during MI
might have upregulated the AA pathway which was evident
by the significantly higher activities of 5-LOX and COX sug-
gesting the strong involvement of AA pathway in the onset of
MI. We found that the levels of LTB4 and TXB2 were raised in
the serum of MI subjects and were undetectable in the serum
of CP and N subjects. Due to the significant increases in the
levels of LTB4 and TXB2, the chances of overlapping of results
can be prevented. This is due to the high sensitivity and
specificity of LTB4 and TXB2. The drawback of the present
study is the small sample size. Investigations including a
larger scale of patients need to be performed to confirm the
use of LTB4 and TXB2 in ruling out the disease and aid in timely
management if MI.Conflicts of interest
All authors have none to declare.
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